HHS Public Access

Author manuscript

Mol Genet Metab. Author manuscript; available in PMC 2021 September 06.

Published in final edited form as:

Mol Genet Metab. 2020 ; 131(1-2): 90–97. doi:10.1016/j.ymgme.2020.09.001.

Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD

Gabriela Elizondo[1], **Dietrich Matern**[2], **Jerry Vockley**[3], **Cary O. Harding**[1], **Melanie B. Gillingham**[1,2]

[1]Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon

[2]Biochemical Genetics Laboratory, Mayo Clinic, Rochester, Minnesota

[3]Department of Pediatrics University of Pittsburgh School of Medicine, Center for Rare Disease Therapy, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

Abstract

Background: The plasma acylcarnitine profile is frequently used as a biochemical assessment for follow-up in diagnosed patients with fatty acid oxidation disorders (FAODs). Disease specific acylcarnitine species are elevated during metabolic decompensation but there is clinical and biochemical heterogeneity among patients and limited data on the utility of an acylcarnitine profile for routine clinical monitoring.

Methods: We evaluated plasma acylcarnitine profiles from 30 diagnosed patients with long-chain FAODs (carnitine palmitoyltransferase-2 (CPT2), very long-chain acyl-CoA dehydrogenase (VLCAD), and long-chain 3-hydroxy acyl-CoA dehydrogenase or mitochondrial trifunctional protein (LCHAD/TFP) deficiencies) collected after an overnight fast, after feeding a controlled low-fat diet, and before and after moderate exercise. Our purpose was to describe the variability in this biomarker and how various physiologic states effect the acylcarnitine concentrations in circulation.

Results: Disease specific acylcarnitine species were higher after an overnight fast and decreased by approximately 60% two hours after a controlled breakfast meal. Moderate-intensity exercise increased the acylcarnitine species but it varied by diagnosis. When analyzed for a genotype/phenotype correlation, the presence of the common LCHADD mutation (c.1528G>C) was associated with higher levels of 3-hydroxyacylcarnitines than in patients with other mutations.

Conclusions: We found that feeding consistently suppressed and that moderate intensity exercise increased disease specific acylcarnitine species, but the response to exercise was highly variable across subjects and diagnoses. The clinical utility of routine plasma acylcarnitine analysis for outpatient treatment monitoring remains questionable; however, if acylcarnitine profiles are measured in the clinical setting, standardized procedures are required for sample collection to be of value.

Corresponding author and reprint requests to: Melanie B. Gillingham, PhD, RD, Department of Molecular and Medical Genetics, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098, Phone: 503-494-1682, FAX: 503-494-7076, gillingm@ohsu.edu.

Keywords

plasma acylcarnitines; free fatty acids; long-chain fatty acid oxidation disorders; CPT2D; LCHADD; TFPD; VLCADD

1. INTRODUCTION

Plasma acylcarnitines are the metabolic product of the import and partial oxidation of fatty acids in the mitochondria. The mitochondrial membrane is impermeable to long chain fatty acids, so the carnitine shuttle is necessary to import fatty acid acyl-CoAs into the mitochondria via carnitine acylcarnitine translocase after conversion to acylcarnitines by the carnitine-palmitoyl CoA transferase 1 (CPT1). Reconversion of acylcarnitines to acyl-CoAs by carnitine-palmitoyl CoA transferase 2 (CPT2) provides very-long chain acyl-CoA dehydrogenase (VLCAD), the initial fatty acid oxidation (FAO) enzyme, and the other β-oxidation enzymes in the mitochondria with the degradable acyl-CoAs to produce cellular energy. Accumulation of specific fatty acyl-CoAs due to a defect in one of the proteins of the carnitine shuttle or the fatty acid oxidation pathway exit the cell as excess acylcarnitines and are measured in an acylcarnitine profile.

The acylcarnitine profile is a powerful screening and diagnostic tool for inherited disorders of fatty acid metabolism characterized by accumulation of specific acylcarnitines. Since the late 1990s, acylcarnitine analysis has become an integral part of newborn screening programs to identify patients early and enable treatment initiation before symptoms occur [1, 2]. Subtle elevations in plasma acylcarnitines have also been correlated with the presence of insulin resistance [3–5]. Originally described as the Randle or glucose-fatty acid cycle, diabetes researchers have hypothesized that an elevation in acylcarnitines reflect incomplete FAO, mitochondrial overload of fatty acids, and evidence of lipotoxicity leading to insulin resistance [4, 6, 7].

While it is clear that acylcarnitines are useful for screening and diagnosis, the utility of this biomarker for disease management has not been established. Data on plasma acylcarnitine concentrations in diagnosed and treated patients with FAODs is scarce and often difficult to interpret. It is well known that acylcarnitines are abnormal during acute metabolic decompensation of patients with FAODs along with other biochemical markers like creatine kinase [8–12], but there is large clinical and biochemical heterogeneity across patients. Levels of long-chain (LC) acylcarnitines decrease during initial therapy after diagnosis, which can be helpful in following the efficiency of early treatment. It is more difficult to evaluate the value of long-term monitoring; acylcarnitines can be three-times the upper normal limit with no obvious clinical signs of disease [9, 11]. Chronically lower acylcarnitine species are associated with better retinal function among subjects with LCHAD deficiency but not with a decrease in incidence of rhabdomyolysis, or other complications of FAODs [13]. Despite these uncertainties, plasma acylcarnitines are frequently used in follow up of diagnosed patients.

Production of acylcarnitines is related to flux through the FAO pathway and multiple physiological factors regulate this process including lipolysis with fasting, level of fitness

with physical activity, and body composition. In patients with FAODs, residual enzyme function might also be an important factor in acylcarnitine production. How these physiologic factors effect FAO flux and plasma acylcarnitine accumulation among patients with FAODs has not been fully explored. Elevated non-esterified free fatty acids (FFA) with accumulation of LC-acylcarnitines after 4 hours of fasting in a patient with LCHADD when compared to a healthy sibling suggests normal or increased lipolysis with fasting among patients with LC-FAODs [14]. We have demonstrated fasting acylcarnitines positively correlate with long-chain fat intake and negatively correlated with MCT intake reported in the previous 3-day food diaries among patients with LCHADD suggesting a potential role of diet in plasma acylcarnitine concentrations [15]. Factors associated with elevations of specific acylcarnitines in FAODs remain unclear.

In this report we evaluated acylcarnitine profiles in plasma from previously diagnosed patients with long-chain fatty-acid oxidation disorders (LC-FAODs) collected in a controlled research setting with the purpose of understanding the natural variability in these biomarkers under various physiological conditions such as feeding, fasting and exercise. Additionally, we compared acylcarnitines with plasma FFA as a marker of lipolysis. This was an additional analysis of plasma acylcarnitines from patients diagnosed with LCHAD/TFP deficiency (OMIM# 600890/609015), VLCAD deficiency (OMIM# 201475) and CPT2 deficiency (OMIM# 255110) who participated in a clinical trial of trioctanoin versus triheptanoin [16].

2. MATERIALS AND METHODS

2.1. Study population

Participants diagnosed with LC-FAOD (n=32) were recruited from several family support networks and physician referral. Because of their similar phenotypes, these participants included patients with carnitine palmitoyltransferase-2 deficiency (CPT2D; n=11), very long-chain acyl-CoA dehydrogenase deficiency (VLCADD; n=9), and long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and trifunctional protein deficiency (LCHADD; n=12) [17]. All participants or their guardians gave written informed consent. Participants younger than 18 years of age also gave assent to participate. This study was approved by the OHSU and UPMC institutional review boards (OHSU eIRB# 817; UPMC eIRB# PRO011020038) and is listed on clinical trials.gov (NCT00654004). Data for this additional analysis was collected during the baseline admission of the study prior to randomization to trioctanoin or triheptanoin; study procedures are outlined in Supplemental Figure 1A.

Participants were admitted to the OHSU or the University of Pittsburgh's Clinical and Translational Research Center (CTRC) where blood samples were collected for this study. All participants were fed a healthy low long-chain fatty acid (LC-FA) diet that included complex carbohydrates (51–72% of total energy intake), protein (9–17% of total energy intake), low dietary long-chain fat (10% of total energy intake) and medium-chain triglyceride (MCT) oil at 20% of total energy to provide a total of 30% of total energy from dietary fat. Carnitine supplementation was not initiated but maintained among 13 subjects

who were already being supplemented (dose 9–82 mg/kg body weight; Supplemental Figure 2A).

During inpatient admissions, all meals were prepared in the CTRCs Bionutrition Research Kitchen. Participants were asked to eat only the food provided to them by the study and nothing else. Total food intake (weight of food dispensed minus weight of uneaten food returned) was recorded and energy and nutrient intakes were calculated using Pronutra® software by the CTRC bionutrition staff (Viocare Technologies, Inc., Princeton, NJ). Participants were provided approximately 110% of estimated energy needs and told to eat until they were full (adlibitum feeding). Subjects were fed this controlled diet for 24 hours prior to blood sampling and throughout the following 24-hour period when blood samples were collected (Supplemental Figure 1A). Weighed macronutrient intake for 30 subjects is shown in Supplemental Figure 1B.

An intravenous catheter was placed in a peripheral arm vein to facilitate multiple blood draws. One participant with VLCADD was excluded because of failure to achieve intravenous catheter access. Blood samples were obtained immediately before consuming the meal (after a 10-hour fasting) and again at 2 and 4 hours post-prandially. Blood samples were also obtained before and after a monitored exercise period consisting of a supervised moderate intensity treadmill exercise test in which subjects walked for 45 minutes. Blood samples were analyzed for plasma acylcarnitine levels and FFA.

2.2. Plasma acylcarnitine analysis

Blood samples were collected in tubes containing heparin. Plasma was obtained and stored at −80 °C until analysis. All plasma samples were analyzed by flow injection analysis tandem mass spectrometry (FIA-MS/MS) and quantified as previously published [18, 19].

2.3. Free fatty acid analysis

Blood samples were collected into EDTA tubes and plasma was separated and a lipase inhibitor added (THL) to prevent ex vivo lipolysis of lipids. Plasma with THL was stored at −80 °C until further analysis. All plasma samples were analyzed by enzymatic colorimetric assay for the quantitative determination of non-esterified fatty acids (NEFA, mEq/L) as previously described (Wako, FLUOstar Omega microplate reader, BMG LabTech).

2.4. Data analysis

Data are reported as mean and standard deviation unless otherwise specified. Change in acylcarnitines over time was analyzed by 1-way repeated measures ANOVA. For all analyses, a $p<0.05$ was considered statistically significant. The normality of the data was tested using the Anderson-Darling and D'Angostino & Pearson normality tests. For all correlations, we used Spearman correlation analysis for non-normally distributed data. Statistical analysis and graphics were completed using Prism 8.4.2 GraphPad Software Inc. (La Jolla, California).

3. RESULTS

Subject genotypes are listed in Table 1. Eleven subjects diagnosed with CPT2D were enrolled into the study (8 female and 3 male). Common pathogenic variants were not found in two of the subjects, but enzyme analysis confirmed the diagnosis with 20% or less enzyme activity compared to normal controls. Age ranged from 9 to 64 years with a mean of 30 years of age. Nine patients diagnosed with VLCADD were recruited. One subject was excluded from this analysis due to inability to obtain vascular access. The participating subjects ranged in age from 7 to 42 years of age with a mean of 31 years. Four of the subjects were female and 4 were male, and each had a unique genotype (Table 1). Twelve subjects diagnosed with LCHADD where enrolled in the study. One subject was excluded because consent for secondary research and additional studies outside of the original project was not provided. Nine of these eleven participants were either homozygous or compound heterozygous for the common pathogenic *HADHA* variant c.1528G>C. Two subjects did not carry the common mutation: a female with a c.901G>A/? genotype and a male with a compound heterozygous genotype (c.1150-1G>1/c.208T>C). These mutations were previously reported as pathogenic variants associated with a TFP deficiency phenotype [20]. The subjects age ranged from 7 to 29 years of age with a mean of 15 years. Six were female and 5 were male. A total of 30 subjects with a long-chain FAOD are included in this analysis.

The range of selected disease specific acylcarnitine species for the 11 CPT2D subjects is graphed in Figure 1. After an overnight fast, the highest long-chain acylcarnitine species was C18:1 (mean 0.76 ± 0.35 μmol/L) which was higher than the normal reference range for plasma (0.02 – 0.38 μmol/L) [19] (Figure 1A). The other two typical acylcarnitine biomarkers used for CPT2D diagnosis, C16 and C18, were also higher than the reference range (0.03 – 0.22 μmol/L and 0.01 – 0.13 μmol/L, respectively). C18:1 decreased by 61% after a breakfast meal and increased more than 223% after exercise (Figure 1B). However, the individual responses to feeding and exercise in particular, were highly variable (Figure 1C). Additionally, we compared NBS ratios used to further discriminate cases of FAODs from healthy neonates to the plasma ratios in treated subjects [1]. In the case of CPT2D, the ratio C0/(C16+C18) was higher than the NBS reference range and the ratio (C16+C18:1)/C2 was within normal range (Supplemental Table 1).

The acylcarnitine profiles for the 8 VLCADD subjects are graphed in Figure 2. Fasting plasma long-chain acylcarnitines were within normal limits except for C14:1 (1.39 ± 1.14 μmol/L) which is higher than the reference range of 0.00 – 0.23 μmol/L (Figure 2A) [19]. Mean C14:1 acylcarnitine concentration after an overnight 10-hour fast fell about 62% after a breakfast meal and increased 133% after moderate intensity exercise (Figure 2B). Again, the individual responses varied, particularly after exercise (Figure 2C). Ratios used in NBS to further discriminate VLCADD include C14:1/C2, C14:1/C12:1 and C14:1/C16. Only the C14:1/C16 ratio remained elevated in these treated VLCADD subjects (Supplemental Table 1).

The acylcarnitine profiles of the 11 subjects with LCHADD are graphed in Figure 3. The most prominent fasting long-chain acylcarnitine was C18:1-OH (0.56 ± 0.52 μmol/L;

reference range of 0.00–0.05 μmol/L) (Figure 3A). C16-OH and C18-OH were higher than the reference range (0.00 – 0.05 μmol/L and 0.00 – 0.02 μmol/L, respectively) [19]. C18:1-OH was elevated after an overnight fast, decreased by 59% after breakfast but had minimal change with moderate intensity exercise (Figure 3B). Unlike the exercise response with CPT2D and VLCADD, this hydroxyacylcarnitine species did not increase much after exercise (20%) and was relatively consistent across subjects (Figure 3C). When comparing the individual genotype of LCHADD/TFP with acylcarnitine levels, all patients with the presence of the common mutation (c.1528G>C) in at least one allele had consistently higher levels of C16-OH, C18:0-OH (Figure 3D) and C18:1-OH than the two patients without the common mutation and a TFPD phenotype but the difference was not statistically significant ($p = 0.09$). Lastly, two acylcarnitine ratios are used to improve diagnostic discrimination of LCHADD in NBS: C16-OH/C16 and C18-OH/C18. These ratios were elevated despite treatment when compared to NBS normal ranges (Supplemental Table 1).

To explore the relationship between lipolysis and LC-acylcarnitines after fasting and exercise, we measured plasma FFA at the same timepoints (Figure 4A). It is well established that lipolysis with fasting and the rise in plasma FFA is directly correlated with a rise in fatty acid oxidation and the production of ketones in the liver [21, 22]. However, after exercise, other factors such as uptake of FFA by muscle (FFA disposal) and use of intramyocellular lipid stores impact muscle FAO during exercise in addition to exercise induced lipolysis. FFAs rise with fasting but the response to a controlled fast is variable across subjects. FFA decrease with feeding and begin to rise again with the relatively short fast between meals. The response to exercise is also highly variable. To compare the global pattern of change in FFA to all LC-acylcarnitines across the whole subject population, we summed all the species C14:0 and greater for a sum of LC-acylcarnitines and graphed this total in Figure 4B. The pattern of change for the sum of the LC-acylcarnitines is similar to the change in FFA, particularly with fasting and feeding. This suggests that lipolysis is a primary factor in the production of acylcarnitine species among patients with LC-FAODs. Next, we correlated the fasting and post-exercise levels of FFA and the sum of the LC-acylcarnitines. FFA and the sum of the LC- acylcarnitines were not normally distributed so we used a Spearman correlation. Fasting FFAs were correlated with the fasting sum of the LC-acylcarnitines (Figure 4C). However, there was no significant correlation of post-exercise FFAs and the post-exercise sum of LC-acylcarnitines after exercise (Figure 4D). The data suggest lipolysis measured by plasma FFA is associated with an increase in acylcarnitines after an overnight fast. However, FFA are not correlated with acylcarnitines post-exercise suggesting other factors are more important drivers of partial fat oxidation in response to moderate physical activity.

We also explored the relationships between carnitine supplementation and acylcarnitines. The free carnitine was higher but the fasting sum of LC-acylcarnitines among the 13 subjects with carnitine supplementation was not different from the 17 subjects not consuming carnitine supplements (Supplemental Figure 2B–C). Creatine kinase (CK) levels were measured after an overnight fast and before and after the moderate intensity treadmill exercise. Fasting CK values in these healthy well controlled subjects were low and there was a lack of a strong correlation with the fasting sum of LC-acylcarnitines. CK levels increased

very little (9%) with exercise. There was no correlation between exercise change in CK, change in LC-acylcarnitines or a measure of fitness (exercise speed *grade).

4. DISCUSSION

Acylcarnitine analysis of dried blood spots on filter paper is an effective NBS tool for early detection of FAODs [23]. Confirmation of the diagnosis, follow-up and long-term management use plasma acylcarnitine analysis rather than dried blood spots [24]. As we have shown, plasma acylcarnitine levels vary depending on the physiologic condition. We found that feeding consistently suppresses disease-specific acylcarnitines by approximately 60% and that moderate intensity exercise increases acylcarnitine species but the response to exercise is highly variable across subjects and FAOD diagnoses. Disease-specific plasma acylcarnitines are highly variable throughout the day changing with the physiologic states of feeding, fasting and activity so timing of a blood sample collection in relation to physiologic state is critical for the interpretation of the resulting acylcarnitine profile.

Our results suggest that a controlled low-fat diet with MCT and regular meals to avoid fasting lowers plasma acylcarnitines in treated patients compared to levels observed in untreated, undiagnosed patients. Some of the long-chain species were within control ranges and many of the metabolic ratios used for enhanced diagnostic discrimination were within control ranges as well. This was particularly true for subjects with CPT2D where there was an almost complete normalization of LC-acylcarnitines associated with CPT2D in response to treatment (C18:1 remains slightly above normal levels, but the elevation is minimal Figure 1A). This correlates with the absence of symptoms in these participants. However, despite lower levels than observed in undiagnosed patients, the plasma acylcarnitine profile did not completely normalize in VLCADD or LCHADD subjects. C14:1, an important marker for VLCADD was still elevated and was associated with a high C14:1/C2 ratio (Figures 2 and Supplemental Table 1). Subjects with LCHADD exhibited elevated long-chain hydroxyacylcarnitines (C16-OH, C18-OH, and C18:1-OH) (Figure 3). All patients with the common mutation (c.1528G>C) in at least one *HADHA* allele had consistently higher levels of C16-OH, C18-OH and C18:1-OH than the two patients without the common pathogenic variant and a TFP phenotype as previously reported [25] ($p = 0.09$; Figure 3D). These findings suggest that mutations that destabilize the protein and result in a loss of mitochondrial TFP expression have low OH-species due to the absence of the hydratase activity. Thus, the plasma acylcarnitine profile will more closely resemble that of a patient with VLCADD [26]. The absence of common mutations in our CPT2D and VLCADD cohorts limit our ability to make similar inferences between genotype and acylcarnitines in those disorders, although genotype-phenotype correlations are continuously being reported and this may be possible in the future [27, 28].

Carnitine supplementation is common among patients with FAODs. It is hypothesized that increase in plasma availability of carnitine would increase FAO flux in the mitochondria which could potentially be observed by increased plasma acylcarnitine levels. We found that free carnitine was higher but there was no difference in the sum of the LC-acylcarnitines (Supplemental Figure 2A–C). Another commonly used physiologic marker in FAODs is CK. This study was conducted in healthy, well-controlled subjects and the exercise test was

designed to be moderate and not induce rhabdomyolysis. This was corroborated with very low fasting CK levels, the absence of symptomatology with exercise and a small change in CK levels (increase of only 9%). Speed * grade was used as a surrogate for fitness assuming that subjects that walked faster at a greater incline to reach 60% estimated max heart rate would be more fit. There was no strong correlation with LC-acylcarnitines and measures of CK or fitness. All patients tolerated the exercise further supporting the current recommendations for patients with FAODs to be physically active which could improve long-term fitness and exercise tolerance.

Seminal papers have demonstrated that adipose tissue lipolysis, and the rise of FFAs with fasting, drives FAO and ketone production in the liver, increasing the flux through the fatty acid oxidation pathway [29–31]. We were interested in the association of lipolysis and plasma LC-acylcarnitines during fasting. FFAs rise with fasting and decrease with feeding (Figure 4A). The sum of all LC-acylcarnitines follow a similar pattern in response to fasting and feeding (Figure 4C). FFAs were positively correlated with the sum of LC-acylcarnitines (Figure 4B) suggesting that lipolysis is driving flux through the FAO pathway after an overnight fast and increasing plasma LC-acylcarnitines. It further suggests that the source of circulating LC-acylcarnitines after fasting may be the liver, although further study is needed to prove this hypothesis. Feeding suppresses lipolysis and plasma LC-acylcarnitines (Figure 4A and 4B), supporting the role of fasting avoidance and frequent meals for lowering LC-acylcarnitines in patients with LC-FAODs.

In contrast, decades of exercise physiology research suggest the activation of the FAO pathway during exercise is more complex. FAO flux is dependent on exercise intensity with moderate intensity exercise activating FAO while high intensity exercise relies on glucose oxidation [32]. Training increases FAO and spares glycogen [33]. Even muscle fiber types effect FAO; slow-twitch fibers are more oxidative and utilize more FA while fast-twitch fibers use almost exclusively glucose. We examined the relationship between lipolysis and moderate exercise but found a very different relationship than we observed with fasting. FFA from lipolysis rose after moderate intensity exercise (Figure 4A) but the rise in LC-acylcarnitines after moderate exercise was extremely variable, particularly in subjects with CPT2D and VLCADD. Interestingly, the rise was consistently lower among subjects with LCHADD. There was no correlation between FFAs and LC-acylcarnitines after exercise suggesting lipolysis is not the main factor driving FAO with exercise, and perhaps that the source of the LC-acylcarnitines is not predominately the liver (Figure 4D). In fact, it has been suggested that adults with VLCADD may have a preponderance of fast-twitch, type 2 muscle fibers that are more glycolytic with moderate exercise than normal healthy controls [34]. Further study is needed to understand the physiologic factors that regulate FAO flux and the appearance of acylcarnitines with exercise among patients with FAODs.

One limitation of this study may also be considered a strength. Subjects were fed a controlled diet and consumed similar macronutrients for the 24 hours before and during blood sampling in this study; we are unable to determine the effect of various dietary intakes on plasma acylcarnitines. Although 30 subjects represent a relatively large population of subjects with LC-FAODs, each individual diagnosis had relatively few subjects limiting the statistical power of this predominately descriptive analysis. One of the limitations of the

field of FAODs in general is the lack of data correlating outcomes with changes in biomarkers such as acylcarnitines. This may be because there is no relationship and that lowering LC-acylcarnitines does not impact outcomes or decrease disease symptoms. It is also possible that a large prospectively followed cohort is needed to demonstrate such a relationship and so far, this type of natural history study has not been conducted. At this point, the only data demonstrating a relationship between elevations in disease specific acylcarnitines and outcomes is the previously mentioned correlation with elevated hydroxyacylcarnitines and decreased retinal function in subjects with LCHADD [13]. Occasional routine plasma acylcarnitine analysis in LC-FAODs may help establish an individual's "typical" acylcarnitine pattern when healthy which can be valuable in cases of intercurrent illness, or metabolic decompensation.

In summary, we have demonstrated that disease-specific plasma acylcarnitines are highly variable throughout the day changing with the physiologic states of feeding, fasting and activity. Thus, blood collection for acylcarnitine profile analysis in the outpatient clinic setting irrespective of when the patient ate or exercised limits interpretation of the results. The utility of random plasma acylcarnitine analysis for outpatient treatment monitoring may not be beneficial and may not offer useful information beyond the patient's clinical evaluation. However, when acylcarnitine profiles are obtained in the clinical setting, it is recommended that standardized procedures for sample collection (i.e., timing in relation to food intake and physical activity) are strictly followed to improve their clinical interpretation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This study was funded by the Food & Drug Administration, Orphan Drug Development Program, Grant FD038950. The authors sincerely thank all the subjects who participated in this trial. Research reported in this publication was also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award numbers UL1TR000128 and UL1TR001857. JV was supported in part by a NIH grant DKR01-78755. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

REFERENCES

[1]. McHugh D, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA, Ahlman H, Allen JJ, Antonozzi I, Archer S, Au S, Auray-Blais C, Baker M, Bamforth F, Beckmann K, Pino GB, Berberich SL, Binard R, Boemer F, Bonham J, Breen NN, Bryant SC, Caggana M, Caldwell SG, Camilot M, Campbell C, Carducci C, Bryant SC, Caggana M, Caldwell SG, Camilot M, Campbell C, Carducci C, Cariappa R, Carlisle C, Caruso U, Cassanello M, Castilla AM, Ramos DE, Chakraborty P, Chandrasekar R, Ramos AC, Cheillan D, Chien YH, Childs TA, Chrastina P, Sica YC, de Juan JA, Colandre ME, Espinoza VC, Corso G, Currier R, Cyr D, Czuczy N, D'Apolito O, Davis T, de Sain-Van der Velden MG, Delgado Pecellin C, Di Gangi IM, Di Stefano CM, Dotsikas Y, Downing M, Downs SM, Dy B, Dymerski M, Rueda I, Elvers B, Eaton R, Eckerd BM, El Mougy F, Eroh S, Espada M, Evans C, Fawbush S, Fijolek KF, Fisher L, Franzson L, Frazier DM, Garcia LR, Bermejo MS, Gavrilov D, Gerace R, Giordano G, Irazabal YG, Greed LC, Grier R, Grycki E, Gu X, Gulamali-Majid F, Hagar AF, Han L, Hannon WH, Haslip C, Hassan FA, He M, Hietala A, Himstedt L, Hoffman GL, Hoffman W, Hoggatt P,

Hopkins PV, Hougaard DM, Hughes K, Hunt PR, Hwu WL, Hynes J, Ibarra-Gonzalez I, Ingham CA, Ivanova M, Jacox WB, John C, Johnson JP, Jonsson JJ, Karg E, Kasper D, Klopper B, Katakouzinos D, Khneisser I, Knoll D, Kobayashi H, Koneski R, Kozich V, Kouapei R, Kohlmueller D, Kremensky I, la Marca G, Lavochkin M, Lee SY, Lehotay DC, Lemes A, Lepage J, Lesko B, Lewis B, Lim C, Linard S, Lindner M, Lloyd-Puryear MA, Lorey F, Loukas YL, Luedtke J, Maffitt N, Magee JF, Manning A, Manos S, Marie S, Hadachi SM, Marquardt G, Martin SJ, Matern D, Mayfield Gibson SK, Mayne P, McCallister TD, McCann M, McClure J, McGill JJ, McKeever CD, McNeilly B, Morrissey MA, Moutsatsou P, Mulcahy EA, Nikoloudis D, Norgaard-Pedersen B, Oglesbee D, Oltarzewski M, Ombrone D, Ojodu J, Papakonstantinou V, Reoyo SP, Park HD, Pasquali M, Pasquini E, Patel P, Pass KA, Peterson C, Pettersen RD, Pitt JJ, Poh S, Pollak A, Porter C, Poston PA, Price RW, Queijo C, Quesada J, Randell E, Ranieri E, Raymond K, Reddic JE, Reuben A, Ricciardi C, Rinaldo P, Rivera JD, Roberts A, Rocha H, Roche G, Greenberg CR, Mellado JM, Juan-Fita MJ, Ruiz C, Ruoppolo M, Rutledge SL, Ryu E, Saban C, Sahai I, Garcia-Blanco MI, Santiago-Borrero P, Schenone A, Schoos R, Schweitzer B, Scott P, Seashore MR, Seeterlin MA, Sesser DE, Sevier DW, Shone SM, Sinclair G, Skrinska VA, Stanley EL, Strovel ET, Jones AL, Sunny S, Takats Z, Tanyalcin T, Teofoli F, Thompson JR, Tomashitis K, Domingos MT, Torres J, Torres R, Tortorelli S, Turi S, Turner K, Tzanakos N, Valiente AG, Vallance H, Vela-Amieva M, Vilarinho L, von Dobeln U, Vincent MF, Vorster BC, Watson MS, Webster D, Weiss S, Wilcken B, Wiley V, Williams SK, Willis SA, Woontner M, Wright K, Yahyaoui R, Yamaguchi S, Yssel M, Zakowicz WM, Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project Genet Med 13 (2011) 230–254. [PubMed: 21325949]

[2]. Hall PL, Marquardt G, McHugh DM, Currier RJ, Tang H, Stoway SD, Rinaldo P, Postanalytical tools improve performance of newborn screening by tandem mass spectrometry Genet Med 16 (2014) 889–895. [PubMed: 24875301]

[3]. Peters V, Vockley J, Do inborn errors of metabolism confer or impede the risk of diabetes? J Inherit Metab Dis 41 (2018) 1–2. [PubMed: 29230604]

[4]. Schooneman MG, Vaz FM, Houten SM, Soeters MR, Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 62 (2013) 1–8. [PubMed: 23258903]

[5]. Schooneman MG, Napolitano A, Houten SM, Ambler GK, Murgatroyd PR, Miller SR, Hollak CE, Tan CY, Virtue S, Vidal-Puig A, Nunez DJ, Soeters MR, Assessment of plasma acylcarnitines before and after weight loss in obese subjects Arch Biochem Biophys 606 (2016) 73–80. [PubMed: 27444119]

[6]. Goetzman ES, Gong Z, Schiff M, Wang Y, Muzumdar RH, Metabolic pathways at the crossroads of diabetes and inborn errors J Inherit Metab Dis 41 (2018) 5–17. [PubMed: 28952033]

[7]. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, Garvey WT, Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women J Nutr 139 (2009) 1073–1081. [PubMed: 19369366]

[8]. De Biase I, Viau KS, Liu A, Yuzyuk T, Botto LD, Pasquali M, Longo N, Diagnosis, Treatment, and Clinical Outcome of Patients with Mitochondrial Trifunctional Protein/Long-Chain 3-Hydroxy Acyl-CoA Dehydrogenase Deficiency JIMD Rep 31 (2017) 63–71. [PubMed: 27117294]

[9]. Lund AM, Skovby F, Vestergaard H, Christensen M, Christensen E, Clinical and biochemical monitoring of patients with fatty acid oxidation disorders J Inherit Metab Dis 33 (2010) 495–500. [PubMed: 20066495]

[10]. Karall D, Mair G, Albrecht U, Niedermayr K, Karall T, Schobersberger W, Scholl-Burgi S, Sports in LCHAD Deficiency: Maximal Incremental and Endurance Exercise Tests in a 13-Year-Old Patient with Long-Chain 3-Hydroxy Acyl-CoA Dehydrogenase Deficiency (LCHADD) and Heptanoate Treatment JIMD reports 17 (2014) 7–12. [PubMed: 24997711]

[11]. Van Hove JL, Kahler SG, Feezor MD, Ramakrishna JP, Hart P, Treem WR, Shen JJ, Matern D, Millington DS, Acylcarnitines in plasma and blood spots of patients with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase defiency J Inherit Metab Dis 23 (2000) 571–582. [PubMed: 11032332]

[12]. Van Hove JL, Zhang W, Kahler SG, Roe CR, Chen YT, Terada N, Chace DH, Iafolla AK, Ding JH, Millington DS, Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine analysis in blood Am J Hum Genet 52 (1993) 958–966. [PubMed: 8488845]

[13]. Gillingham MB, Weleber RG, Neuringer M, Connor WE, Mills M, van Calcar S, Ver Hoeve J, Wolff J, Harding CO, Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency Mol Genet Metab 86 (2005) 124–133. [PubMed: 16040264]

[14]. Halldin MU, Forslund A, von Dobeln U, Eklund C, Gustafsson J, Increased lipolysis in LCHAD deficiency J Inherit Metab Dis 30 (2007) 39–46. [PubMed: 17160563]

[15]. Gillingham MB, Connor WE, Matern D, Rinaldo P, Burlingame T, Meeuws K, Harding CO, Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency Mol Genet Metab 79 (2003) 114–123. [PubMed: 12809642]

[16]. Gillingham MB, Heitner SB, Martin J, Rose S, Goldstein A, El-Gharbawy AH, Deward S, Lasarev MR, Pollaro J, DeLany JP, Burchill LJ, Goodpaster B, Shoemaker J, Matern D, Harding CO, Vockley J, Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial J Inherit Metab Dis (2017).

[17]. Gillingham MB, Heitner SB, Martin J, Rose S, Goldstein A, El-Gharbawy AH, Deward S, Lasarev MR, Pollaro J, DeLany JP, Burchill LJ, Goodpaster B, Shoemaker J, Matern D, Harding CO, Vockley J, Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial J Inherit Metab Dis 40 (2017) 831–843. [PubMed: 28871440]

[18]. Rinaldo P, Cowan TM, Matern D, Acylcarnitine profile analysis Genet Med 10 (2008) 151–156. [PubMed: 18281923]

[19]. Smith EH, Matern D, Acylcarnitine analysis by tandem mass spectrometry Curr Protoc Hum Genet Chapter 17 (2010) Unit 17 18 11–20.

[20]. Ibdah JA, Zhao Y, Viola J, Gibson B, Bennett MJ, Strauss AW, Molecular prenatal diagnosis in families with fetal mitochondrial trifunctional protein mutations J Pediatr 138 (2001) 396–399. [PubMed: 11241049]

[21]. Haglind CB, Nordenstrom A, Ask S, von Dobeln U, Gustafsson J, Stenlid MH, Increased and early lipolysis in children with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency during fast J Inherit Metab Dis 38 (2015) 315–322. [PubMed: 25141826]

[22]. Votruba SB, Jensen MD, Regional fat deposition as a factor in FFA metabolism Annu Rev Nutr 27 (2007) 149–163. [PubMed: 17506663]

[23]. Ryder B, Knoll D, Love DR, Shepherd P, Love JM, Reed PW, de Hora M, Webster D, Glamuzina E, Wilson C, The natural history of elevated tetradecenoyl-L-carnitine detected by newborn screening in New Zealand: implications for very long chain acyl-CoA dehydrogenase deficiency screening and treatment J Inherit Metab Dis 39 (2016) 409–414. [PubMed: 26743058]

[24]. de Sain-van der Velden MG, Diekman EF, Jans JJ, van der Ham M, Prinsen BH, Visser G, Verhoeven-Duif NM, Differences between acylcarnitine profiles in plasma and bloodspots Mol Genet Metab 110 (2013) 116–121. [PubMed: 23639448]

[25]. Gillingham MB, Matern D, Harding CO, Effect of Feeding, Exercise and Genotype on Plasma 3-Hydroxyacylcarnitines in Children with Lchad Deficiency Top Clin Nutr 24 (2009) 359–365. [PubMed: 20589231]

[26]. Spiekerkoetter U, Khuchua Z, Yue Z, Bennett MJ, Strauss AW, General mitochondrial trifunctional protein (TFP) deficiency as a result of either alpha- or beta-subunit mutations exhibits similar phenotypes because mutations in either subunit alter TFP complex expression and subunit turnover Pediatr Res 55 (2004) 190–196. [PubMed: 14630990]

[27]. Pena LD, van Calcar SC, Hansen J, Edick MJ, Walsh Vockley C, Leslie N, Cameron C, Mohsen AW, Berry SA, Arnold GL, Vockley J, Ibemc, Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database Mol Genet Metab 118 (2016) 272–281. [PubMed: 27209629]

[28]. Rovelli V, Manzoni F, Viau K, Pasquali M, Longo N, Clinical and biochemical outcome of patients with very long-chain acyl-CoA dehydrogenase deficiency Mol Genet Metab 127 (2019) 64–73. [PubMed: 31031081]

[29]. McGarry JD, Foster DW, Regulation of hepatic fatty acid oxidation and ketone body production Annu Rev Biochem 49 (1980) 395–420. [PubMed: 6157353]

[30]. McGarry JD, Leatherman GF, Foster DW, Carnitine palmitoyltransferase I The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA J Biol Chem 253 (1978) 4128–4136. [PubMed: 659409]

[31]. McGarry JD, Meier JM, Foster DW, The effects of starvation and refeeding on carbohydrate and lipid metabolism in vivo and in the perfused rat liver. The relationship between fatty acid oxidation and esterification in the regulation of ketogenesis J Biol Chem 248 (1973) 270–278. [PubMed: 4692833]

[32]. Spriet LL, New insights into the interaction of carbohydrate and fat metabolism during exercise Sports Med 44 Suppl 1 (2014) S87–96. [PubMed: 24791920]

[33]. Jeukendrup AE, Saris WH, Wagenmakers AJ, Fat metabolism during exercise: a review--part II: regulation of metabolism and the effects of training Int J Sports Med 19 (1998) 293–302. [PubMed: 9721051]

[34]. Diekman EF, Visser G, Schmitz JP, Nievelstein RA, de Sain-van der Velden M, Wardrop M, Van der Pol WL, Houten SM, van Riel NA, Takken T, Jeneson JA, Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency PLoS One 11 (2016) e0147818. [PubMed: 26881790]



Figure 1. Fasting and exercise variability of plasma acylcarnitines in patients with CPT2D

Data are presented as mean ± standard deviation. Reference range is presented as pink shading. A) Selected very long-chain acylcarnitines of CPT2D subjects (n=11) after 10 hours of fasting. C18:1 has the highest concentration overall (0.76 ± 0.35 μmol/L). B) C18:1 is higher than reference range of 0.02–0.38 μmol/L. C18:1 decreased by 61% after a breakfast meal and exercise increased levels by 223%. C) Individual subject values of C18:1 are plotted. C18:1 varies substantially between fasting and 2 hours post-prandially and also before and after moderate intensity exercise (1-way repeated measures ANOVA *p<0.05; **p<0.005; ***p<0.0005).



Figure 2. Fasting and exercise variability of plasma acylcarnitines in patients with VLCADD

Data are presented as mean ± standard deviation. Reference range is presented as pink shading. A) Selected very long-chain acylcarnitines are shown in VLCADD subjects after 10 hours of fasting (n=8). C14:1 was consistently the highest acylcarnitine species: 1.39 ± 1.14 μmol/L (reference range 0.00–0.23 μmol/L). B) Feeding decreased C14:1 level by 62% and exercise increased levels by 133%. In spite of feeding subjects a controlled low fat high MCT diet, mean C14:1 did not normalize. C) Individual responses of C14:1 concentration varied (1-way repeated measures ANOVA, p= 0.025). The fasting C14:1 level was significantly higher than the 2-hour post-prandial or the pre-exercise sample taken 2 hours post lunch. *p<0.05



Figure 3. Fasting and exercise variability of plasma acylcarnitines in patients with LCHADD

Data are presented as mean ± standard deviation. Reference range is presented as pink shading. A) Selected long-chain acylcarnitines in treated LCHADD subjects (n=11) after fasting for 10 hours. The long-chain 3-hydoxyacylcarnitines remain elevated in spite of treatment; C18:1OH was the highest hydroxylated species. B) Data show C18:1-OH values at fasting, 2 and, 4 hours postprandially and before and after moderate exercise (hours 7 and 8) for each of the 11 subjects diagnosed with LCHADD. C18:1-OH ranged from 0.201–0.559 µmol/L. C18:1-OH was elevated after an overnight fast, decreased on average 59% following breakfast but increased by only 20% after moderate intensity exercise. C) Individual subject values are plotted. The fasting C18:1-OH level was significantly higher than the 2-hour and 4-hour post-prandial as well as the post-exercise sample (1-way repeated measures ANOVA *$p<0.05$). D) Changes in C18:0-OH are graphed by genotype. Nine out of the 11 subjects had at least one allele with the common mutation (c.1528G>C; LCHADD) with a fasting C18:0-OH mean of 0.229 µmol/L. The 2 subjects without the common mutation (TFPD) are graphed in red and are on the low end on the spectrum with a fasting C18-OH mean of 0.016 µmol/L. The difference among them is not statistically significant ($p = 0.09$) but may be due to the small sample size and population heterogeneity.



Figure 4. Fasting and exercise correlations of free fatty acids and the sum of long-chain acylcarnitines by LC-FAODs

Data are presented as mean ± standard deviation. A) Plasma FFA concentrations in each group measured at the same timepoints as acylcarnitines. FFA rise with fasting and decrease with feeding but the response is variable. The same is observed in response to exercise. B) The sum of LC-acylcarnitines was obtained by adding all the species C14:0 and greater and followed a similar pattern of change with feeding and exercise as seen with FFA. C) There is a positive correlation between the fasting sum of all of the LC-acylcarnitines and free fatty acids. D) However, there is no correlation between the sum of LC-acylcarnitines and free fatty acids after exercise.

Table 1.

Subject characteristics, diagnosis and genotype

Dx	Gender	Age	Age at Dx	Mutations or Enzyme assay
CPT2D	F	39	28	common mut not detected *; 20% of control activity
	F	41	40	c.338C>T/c.1238_1239delAG (p.S113L/p.Q413fs)
	F	24	15	c.338C>T/? (p.S113L/?); 16% of control activity
	F	43	42	c.338C>T/c.1239>1240delGA (p.S113L/p.K414fs)
	F	41	31	c.338C>T/c.1511C>T (p.S113L/p.P504L)
	M	9	6	c.338C>T/c.340+3A>T (p.S113L/intron 3); 21% of control activity
	F	21	10	common mut not detected *; 7% of control activity
	M	15	13	c.338C>T/c.1239_1240delGA/c.1342T>C (p.S113L/ p.K414fs/p.F448L)
	M	19	17	c.338C>T/c.1666_1667delTT (p.S113L/p.L556fs)
	F	16	2	c.338C>T/c.1666_1667delTT (p.S113L/p.L556fs)
	F	64	63	c.338C>T/c.338C>T (p.S113L/p.S113L)
VLCADD	M	42	30	c.694G>A/c.1388G>A (p.A232T/p.G463E)
	F	7	NBS	c.1619T>C/c.1708_1716dupGACGGGGCC (p.L540P/p.D570_A575dup)
	M	38	36	c.343delG/c.1244C>T (p.E115Kfs/p.A415V)
	F	27	15	c.898A>C/c.1097G>A (p.M300V/p.R366H)
	F	39	34	c.637G>A/c.1065_1067delCAT (p.A213T/p.I356del)
	M	42	38	c.637G>A/c.1065_1067delCAT (p.A213T/p.I356del)
	F	23	23	c.1500_1502delCTT/c.1500_1502delCTT (p.L502del/p.L502del)
	M	32	1	c.1322G>A/c.1837C>T (p.G441D/p.R613W)
LCHADD	M	7	3	c.1528G>C/c.703C>T (p.E510Q/p.R235W)
	F	11	NBS	c.1528G>C/c.1528G>C (p.E510Q/p.E510Q)
	M	9	NBS	c.1528G>C/c.1528G>C (p.E510Q/p.E510Q)
	M	11	7 months	c.1528G>C/c.1528G>C (p.E510Q/p.E510Q)
	F	17	8 months	c.1528G>C/c.1528G>C (p.E510Q/p.E510Q)
	M	23	6 months	c.1528G>C/? (p.E510Q/?)
	F	8	NBS	c.1528G>C/? (p.E510Q/?)
	F	24	6 months	c.1528G>C/c.479_482TAG>AATA (p.E510Q/p.I160fs)
	F	16	2	c.901G>A/? (p.G301S/?)
	F	29	NBS	c.1528G>C/c.1528G>C (p.E510Q/p.E510Q)
	M	16	15	c.1150–1G>T/c.208T>C (intron11/S70P)

Dx = Diagnosis; CPT2D = Carnitine palmitoyltransferase 2 deficiency; VLCADD = Very long-chain acyl-CoA- dehydrogenase deficiency; LCHADD = Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency; F = Female; M = Male;

* common mutations p. 113S>L, p. 50P>H and p. 413 Q >fs were not detected.